Resistance to Mupirocin among Methicillin Resistant Staphylococcus Aureus Isolates from Community Acquired Infections, Hospital Acquired Infections, and colonized Health Care Workers
Shalaby, M., El Shahat, D. (2018). Resistance to Mupirocin among Methicillin Resistant Staphylococcus Aureus Isolates from Community Acquired Infections, Hospital Acquired Infections, and colonized Health Care Workers. EKB Journal Management System, 27(2), 65-69. doi: 10.21608/ejmm.2018.285543
Marwa M. Shalaby; Dina A. El Shahat. "Resistance to Mupirocin among Methicillin Resistant Staphylococcus Aureus Isolates from Community Acquired Infections, Hospital Acquired Infections, and colonized Health Care Workers". EKB Journal Management System, 27, 2, 2018, 65-69. doi: 10.21608/ejmm.2018.285543
Shalaby, M., El Shahat, D. (2018). 'Resistance to Mupirocin among Methicillin Resistant Staphylococcus Aureus Isolates from Community Acquired Infections, Hospital Acquired Infections, and colonized Health Care Workers', EKB Journal Management System, 27(2), pp. 65-69. doi: 10.21608/ejmm.2018.285543
Shalaby, M., El Shahat, D. Resistance to Mupirocin among Methicillin Resistant Staphylococcus Aureus Isolates from Community Acquired Infections, Hospital Acquired Infections, and colonized Health Care Workers. EKB Journal Management System, 2018; 27(2): 65-69. doi: 10.21608/ejmm.2018.285543

Resistance to Mupirocin among Methicillin Resistant Staphylococcus Aureus Isolates from Community Acquired Infections, Hospital Acquired Infections, and colonized Health Care Workers

Egyptian Journal of Medical Microbiology
Volume 27, Issue 2, April 2018, Page 65-69  XML PDF (231.82 K)
Document Type: New and original researches in the field of Microbiology.
DOI: 10.21608/ejmm.2018.285543
View on SCiNiTO View on SCiNiTO
Authors
Marwa M. Shalaby email 1; Dina A. El Shahat2
1Department of Microbiology and Immunology, Faculty of Medicine, Tanta University, Egypt
2Department of Clinical Pathology, Faculty of Medicine, Tanta University, Egypt
Abstract
Background: Mupirocin is prescribed as a topical treatment of Staphylococcus aureus infections as well as in decolonization of methicillin-resistant S. aureus (MRSA) in both patients and health care workers (HCWs). Availability and increased use of this drug has led to emergence of resistance especially among MRSA compared to methicillin sensitive S. aureus (MSSA). Objectives: Our study aimed to evaluate the prevalence of mupirocin resistant MRSA isolated from clinical infections and from colonized HCWs. Methodology: Between January to August 2017, 61 MRSA isolates were collected. Mupirocin MICs were detected using mupirocin E-test. mupA PCR was performed for resistant isolates. Results: 86.9%of MRSA were isolated from clinical infections; 22.9% were Community acquired (CA-MRSA) and 64% were Health Care acquired (HCA-MRSA). 13.1% of total isolated MRSA were from HCWs. 23% of all MRSA were mupirocin resistant. The percentages of mupirocin resistance in CA-MRSA, HCA-MRSA, and MRSA nasal carriers of HCWs were 1.6%, 18.1%, 3.3% of the total Mupirocin resistant MRSA, respectively. 14.8% of MRSA showed low level resistance, while 8.2% were high level Mupirocin resistant. MupA gene was detected in 42.9% of strains with high level mupirocin resistance. Conclusions: Routine MRSA testing for mupirocin resistance is recommended for early detection and control of the spread of resistance.
Keywords
Methicillin-resistant S. aureus (MRSA); Mupirocin; Resistance
Statistics
Article View: 34
PDF Download: 27